A short rebound in stocks fizzled after Monday's drop, as worries about the disruptive impact of artificial intelligence continued to unsettle markets which digested yesterday’s AI scare, and await today’s Claude / Anthropic presentation, while preparing for tonight’s State of the Union address (“SOTU”). Some have suggested that Trump may attack power generation risks during SOTU as he deals with affordability.As of 8:00am ET, S&P 500 futures traded unchanged, erasing an earlier 0.3% gain. The benchmark fel ...

Core Viewpoint - China Medical System Holdings Limited's subsidiary, Dermavon Holdings Limited, has received acceptance from the National Medical Products Administration of China for the New Drug Application of ruxolitinib phosphate cream for treating mild to moderate atopic dermatitis, which is expected to accelerate the marketing approval process [1][4]. Group 1: Product Development and Approval - Ruxolitinib phosphate cream has been approved for marketing by the NMPA for the treatment of vitiligo and is now expanding its indications to atopic dermatitis, marking a significant milestone in its therapeutic applications [2]. - The NDA for ruxolitinib phosphate cream has been included in the Priority Review List, reducing the review timeline from 200 days to 130 days, which is anticipated to expedite the product's availability to patients [4]. Group 2: Clinical Trial Results - The product demonstrated robust efficacy in a Phase III clinical trial, achieving a significantly higher proportion of subjects reaching an Investigator's Global Assessment score of 0 or 1 compared to placebo (63.0% vs 9.2%, P < 0.001) [6]. - For the secondary endpoint, 78.0% of subjects treated with ruxolitinib phosphate cream achieved at least a 75% improvement in the Eczema Area and Severity Index score compared to 15.4% in the placebo group (P < 0.001) [6]. Group 3: Market Potential and Strategic Positioning - Atopic dermatitis affects over 54 million patients in China, with mild to moderate cases accounting for 98% of these, indicating a substantial market opportunity for ruxolitinib phosphate cream [5]. - Dermavon is developing a comprehensive "treatment + care" solution for atopic dermatitis, which includes ruxolitinib phosphate cream and other therapeutic options, enhancing its leadership in dermatology [6][7]. - The acceptance of the NDA for atopic dermatitis is expected to strengthen Dermavon's strategic positioning in skin treatments and create synergies with its existing product portfolio, potentially enhancing market competitiveness [8].

Management attributes marketing leverage gains to long-term brand investment, allowing for a 7-point year-over-year improvement in marketing as a percentage of revenue.The acquisition of Eucalyptus is intended to establish category leadership in Australia and Japan, positioning the international segment to reach $1 billion in annual revenue within three years.Strategic verticalization through $300 million in facility investments has enabled the company to lower costs and deliver custom pharmaceutical-supple ...

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 24, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement issued this morning by Sarborg Limited regarding the expansion of its proprietary AI Signature Agent platform beyond pharmaceuticals into bacteria and agrochemicals. CDT holds a significant 20% equity stake in Sarborg and views this expansion as a meaningful strategic development in the continued evolution of Sarborg’s cross-industry signature int ...

Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution F EB RUARY 24, 2026 Agenda Introduction | Sanj K. Patel, Chief Executive Officer IL-1α & IL-1β Inhibition Franchise | Ross Moat, Chief Operating Officer Fourth Quarter and Full Year 2025 Financial Results | Mark Ragosa, Chief Financial Officer Closing Remarks | Sanj K. Patel, Chief Executive Officer Q&A Session 2 Forward Looking Statements This presentation (together with any other statements or information that we may make i ...

On CNBC's “Halftime Report Final Trades,” Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, named Amazon.com, Inc. (NASDAQ:AMZN) as his final trade.As per the recent news, Amazon.com announced a $12 billion investment in northwest Louisiana on Monday. The investment is earmarked for the development of data centers, which are projected to generate 540 full-time positions and support an additional 1,710 full-time equivalent roles in the community.Bryn Talkington, managing partner ...

In this articleDIACOINLLYNVOZSMETAAMDNVDAThis is CNBC's Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.Happy Tuesday. I found yesterday's snowfall to be quite idyllic, granted I didn't actually step foot outside until it had stopped (don't repeat that to my many colleagues who found themselves on shoveling duty).S&P 500 futures are little changed this morning following a losing day.Here are five key things investors need to know to start the trading day:1. Manic MondayTra ...

Core Viewpoint - AbbVie is a large pharmaceutical company with a diverse product portfolio, and its attractive dividend yield of 2.9% makes it appealing to dividend investors [1][2]. Dividend Yield Comparison - AbbVie's dividend yield of 2.9% is significantly higher than the S&P 500's yield of 1.1% and the average pharmaceutical company's yield of 1.7%, providing investors with 1.8 percentage points more than the broader market and 1.2 percentage points more than the average drug stock [2]. Dividend Sustainability - AbbVie has a history of reliable dividend growth, with a 200% increase over the past decade, indicating a strong commitment to rewarding investors [4]. - The payout ratio exceeds 100%, but when considering the cash dividend payout ratio, which is around 60%, the sustainability of the dividend appears more favorable [5]. Business Stability - AbbVie's esthetics business, particularly Botox, offers a stable cash flow foundation despite the loss of patent protection, suggesting resilience against typical patent cycle impacts faced by other drugmakers [6]. Investment Potential - AbbVie presents an opportunity for healthcare diversification in dividend portfolios, with an attractive yield and potential for a growing dividend stream, making it a solid choice for long-term, income-focused investors [7].

Novo Nordisk to cut US list prices of Ozempic, Wegovy as of 2027 | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, November 24, 2025. REUTERS/Tom Little/File Photo [Purchase Licensing Rights, opens new tab]COPENHAGEN, Feb 24 (Reuters) - Danish drugmaker Novo Nordisk [(NOVOb.CO), opens new tab] sa ...

Core Insights - Artelo Biosciences, Inc. is advancing its clinical-stage pharmaceutical programs with positive human data and upcoming clinical catalysts, focusing on treatments for cancer, pain, and other conditions [1] Business Highlights - Successful completion of a Phase 1 study for ART26.12, showing a favorable safety profile and predictable pharmacokinetics, with plans to initiate a multiple ascending dose study in Q3 2026 [2] - Positive interim Phase 2 results for ART27.13, demonstrating improvements in body weight, lean body mass, and physical activity in patients with cancer anorexia-cachexia syndrome [3] - Received favorable regulatory guidance from the UK MHRA for ART12.11, with plans to initiate human clinical studies in H1 2027 [4] Clinical Progress - ART26.12 has shown sustained analgesic effects comparable to naproxen without tolerance in preclinical models, positioning it as a non-opioid alternative for pain management [5] - ART27.13 has received a Notice of Allowance from the European Patent Office, extending patent protection through December 2041, which has increased partner interest in its development [5] - ART12.11 has demonstrated robust antidepressant-like activity in preclinical studies, with plans for first-in-human studies early next year [5] Financial Results - Research and development expenses for FY 2025 were $5.4 million, down from $6.0 million in FY 2024 [6] - General and administrative expenses increased to $6.0 million in FY 2025 from $4.1 million in the previous year [6] - The net loss for FY 2025 was $12.9 million, or $12.52 per share, compared to a net loss of $9.8 million in FY 2024 [6] - Cash and investments totaled $0.6 million as of December 31, 2025 [6] Product Information - ART26.12 is a lead FABP5 inhibitor aimed at treating chemotherapy-induced peripheral neuropathy, with a favorable safety profile and dosing flexibility [8] - ART27.13 is a cannabinoid receptor agonist targeting cancer-related anorexia and cachexia, showing a mean weight gain of over 6% in the top dose group compared to a 5% loss in the placebo group [9][10] - ART12.11 is a proprietary cocrystal composition of CBD and TMP, with enhanced pharmacokinetics and plans for clinical studies in 2026 [11]